Ivonescimab, a bispecific antibody targeting both PD-1 and VEGF, has emerged as a promising therapeutic agent, demonstrating a favorable safety profile and efficacy in the treatment of advanced solid tumors, including HCC [137]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.